Proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) are one of the most maturely made TPD methods. With this evaluate, we deal with both preclinical experiments and clinical trials to supply a comprehensive summary of the safety and clinical usefulness of PROTACs and MGDs in hematologic malignancies over the past twenty yea